Antibody-Free Profiling of Lysine Dimethylation in Cancer Cell Lines

A proteomics dataset containing site-specific lysine dimethylation (Kme2) events identified in HeLa and A549 cell lines using a chemoselective oxidation and reversible enrichment strategy. The dataset includes quantitative analysis of Kme2 sites sensitive to methylation inhibitor Adox and comparisons between breast cancer cell models. It was authored by Qi Li and last updated on June 3, 2026.

Use Cases

• Identify lysine dimethylation sites based on the described antibody-free proteomics strategy.
• Quantify changes in Kme2 events based on the reported sensitivity to the methylation inhibitor Adox.
• Compare epigenetic profiles between cancer cell models based on the analysis of metastatic MDA-MB-231 cells.
• Investigate the role of Kme2 in cytoskeletal, metabolic, and translational adaptation based on the findings described.

Strengths

• Reports 293 and 284 site-specific Kme2 events identified in HeLa and A549 cells, respectively.
• Describes a quantitative analysis enabling precise characterization of Kme2 sites.
• The antibody-free platform achieved high specificity and good reproducibility as stated.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small in scale at 518.2 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Developed via a proteomics strategy combining selective fluorine-mediated oxidation with reversible hydrazide enrichment.

Freshness

Last updated 2026-06-03 18:35:06; freshness should be verified.